Tagatose, a new antidiabetic and obesity control drug
- 17 October 2007
- journal article
- review article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 10 (2), 109-134
- https://doi.org/10.1111/j.1463-1326.2007.00799.x
Abstract
A potentially important new drug for treating type 2 diabetes, tagatose, is now in phase 3 clinical trial. The history, development, additional health benefits, mechanisms of action and the potential for the drug are presented in context with a review of the rapidly growing epidemic of type 2 diabetes and treatments for it. An epimer of fructose, the natural hexose tagatose was originally developed by Spherix Incorporated (formerly Biospherics Inc.) as a low-calorie sugar substitute. Only 20% of orally ingested tagatose is fully metabolized, principally in the liver, following a metabolic pathway identical to that of fructose. Following a decade of studies, tagatose became generally recognized as safe for use in foods and beverages under US FDA regulation. The simple sugar is commercially produced by isomerization of galactose, which is prepared from lactose. Early human studies suggested tagatose as a potential antidiabetic drug through its beneficial effects on postprandial hyperglycaemia and hyperinsulinaemia. A subsequent 14-month trial confirmed its potential for treating type 2 diabetes, and tagatose showed promise for inducing weight loss and raising high-density lipoprotein cholesterol, both important to the control of diabetes and constituting benefits independent of the disease. Furthermore, tagatose was shown to be an antioxidant and a prebiotic, both properties cited in the maintenance and promotion of health. No current therapies for type 2 diabetes provide these multiple health benefits. The predominant side effects of tagatose are gastrointestinal disturbances associated with excessive consumption, generally accommodated within 1- to 2-week period. The health and use potentials for tagatose (branded Naturlose((R)) for this use) are given with respect to current type 2 diabetes drugs and markets. Under an FDA-affirmed protocol, Spherix is currently conducting a phase 3 trial to evaluate a placebo-subtracted treatment effect based on a decrease in HbA(1c) levels. Side effects, contraindications and possibly beneficial new findings will be carefully monitored. It is hoped that early results of the trial may become available by mid-2008. If a subsequent NDA is successful, tagatose may fill a major health need.Keywords
This publication has 97 references indexed in Scilit:
- Molecular regulation of HDL metabolism and function: implications for novel therapiesJCI Insight, 2006
- Catalytic amounts of fructose may improve glucose tolerance in subjects with uncontrolled non-insulin-dependent diabetesClinical Nutrition, 2006
- Tagatose and milk allergyAllergy, 2005
- Acute Fructose Administration Decreases the Glycemic Response to an Oral Glucose Tolerance Test in Normal AdultsJournal of Clinical Endocrinology & Metabolism, 2000
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Effect of Degree of Weight Loss on Health BenefitsObesity Research, 1995
- Stimulation of glucose phosphorylation by fructose in isolated rat hepatocytesEuropean Journal of Biochemistry, 1989
- The Effect of Artificial Sweetener on Insulin SecretionII. Stimulation of Insulin Release from Isolated Rat Islets by Acesulfame K (In Vitro Experiments)Hormone and Metabolic Research, 1987
- The Effect of Artificial Sweetener on Insulin Secretion 1. The Effect of Acesulfame K on Insulin Secretion in the Rat (Studies In Vivo)Hormone and Metabolic Research, 1987
- Gluconeogenesis from D‐Tagatose by isolated rat and hamster liver cellsFEBS Letters, 1975